A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 3, 2012, Pages 318-327

  Lin, Yu Ling ^a   Liu, Yen Ku ^a   Tsai, Nu Man ^b,c   Hsieh, Jui Hung ^a   Chen, Chia Hung ^a   Lin, Ching Min ^a   Liao, Kuang Wen ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antitumor; Apoptosis; Curcumin; Cytotoxicity; Lipo PEG PEI complex

Indexed keywords

ANTI-TUMORS; ANTITUMOR DRUGS; ANTITUMOR EFFECT; AVERAGE SIZE; CANCER THERAPY; CELL-CYCLE ARREST; CURCUMIN; CYTOTOXIC ACTIVITIES; DELIVERY METHODS; ENCAPSULATION EFFICIENCY; ENCAPSULATION TECHNOLOGY; IN-VIVO; LIPO-PEG-PEI COMPLEX; TUMOR GROWTH;

CELL DEATH; CYTOTOXICITY; ZETA POTENTIAL;

ENCAPSULATION;

CURCUMIN; LIPOSOME; MACROGOL; POLYETHYLENEIMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LEVEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO CULTURE; MOUSE; NANOENCAPSULATION; NEOPLASM; NONHUMAN; PARTICLE SIZE; PECAN; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE;

MUS;

EID: 84858616110     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.06.011     Document Type: Article

References (43)

1. Rosenberg B. Noble metal complexes in cancer chemotherapy. Adv Exp Med Biol 1977, 91:129-150.
2. Schuchter L.M. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Eur J Cancer 1996, 32A:S40-s42.
3. Gamelin L., Capitain O., Morel A., Dumont A., Traore S., Anne le B., et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007, 13:6359-6368.
4. Wang D., Veena M.S., Stevenson K., Tang C., Ho B., Suh J.D., et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 2008, 14:6228-6236.
5. Sahu A., Bora U., Kasoju N., Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 2008, 4:1752-1761.
6. Sou K., Inenaga S., Takeoka S., Tsuchida E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm 2008, 4:1752-1761.
7. Kumar V., Lewis S.A., Mutalik S., Shenoy D.B., Venkatesh U.N. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol 2002, 46:209-217.
8. Li L., Ahmed B., Mehta K., Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007, 6:1276-1282.
9. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
10. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M., et al. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995, 84:493-498.
11. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumors. Proc Natl Acad Sci USA 1988, 85:6949-6953.
12. Lungwitz U., Breunig M., Blunk T., Göpferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005, 60:247-266.
13. Harashima H., Shinohara Y., Kiwada H. Intracellular control of gene trafficking using liposomes as drug carriers. Eur J Pharm Sci 2001, 13:85-89.
14. Fewell J.G., Matar M., Slobodkin G., Han S.O., Rice J., Hovanes B., et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J Control Release 2005, 109:288-298.
15. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
16. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kB-regulated gene products. Cancer Res 2007, 67:3853-3861.
17. Shankar S., Srivastava R.K. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007, 30:905-918.
18. Dhandapani K.M., Mahesh V.B., Brann D.W. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 2007, 102:522-538.
19. Marín Y.E., Wall B.A., Wang S., Namkoong J., Martino J.J., Suh J., et al. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res 2007, 17:274-283.
20. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998, 64:353-356.
21. Liu Y.K., Lin Y.L., Chen C.H., Lin C.M., Ma K.L., Chou F.H., et al. A unique and potent protein binding nature of liposome 1 containing polyethylenimine and polyethylene glycol: a nondisplaceable property. Biotechnol Bioeng 2011, 108:1318-1327.
22. Shao J., Zheng D., Jiang Z., Xu H., Hu Y., Li X., et al. Curcumin delivery by methoxy polyethylene glycol-poly(caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim Biophys Sin (Shanghai) 2011, 43:267-274.
23. Li L., Braiteh F.S., Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on perliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104:1322-1331.
24. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A. Polymeric nanoparticle-encapsulated curcumin (' nanocurcumin' ): a novel strategy for human cancer therapy. J Nanobiotechnology 2007, 5:3.
25. Ma Z., Haddadi A., Molavi O., Lavasanifar A., Lai R., Samuel J. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res A 2008, 86:300-310.
26. Salmaso S., Bersani S., Semenzato A., Caliceti P. New cyclodextrin bioconjugates for active tumour targeting. J Drug Target 2007, 15:379-390.
27. Kim T.H., Jiang H.H., Youn Y.S., Park C.W., Tak K.K., Lee S., et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011, 403:285-291.
28. Yallapu M.M., Othman S.F., Curtis E.T., Gupta B.K., Jaggi M., Chauhan S.C. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 2011, 32:1890-1905.
29. Zhang F., Koh G.Y., Jeansonne D.P., Hollingsworth J., Russo P.S., Vicente G., et al. A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity. J Pharm Sci 2011, 10.1002/jps.22512.
30. Shehzad A., Wahid F., Lee Y.S. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm 2010, 343:489-499.
31. Mourtas S., Canovi M., Zona C., Aurilia D., Niarakis A., La Ferla B., et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials 2011, 32:1635-1645.
32. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998, 95:4607-4612.
33. Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998, 101:1401-1413.
34. Jee S.H., Shen S.C., Tseng C.R., Chin H.C., Kuo M.L. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol 1998, 111:656-661.
35. Holy J.M. Curcumin disrupts mitotic spindle structure and induces micronucleation in MCF-7 breast cancer cells. Mutat Res 2002, 518:71-84.
36. Choudhuri T., Pal S., Das T., Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1 expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005, 280:20059-20068.
37. Van Erk M.J., Teuling E., Staal Y.C., Huybers S., Van Bladeren P.J., Aarts J.M., et al. Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells. J Carcinog 2004, 3:8-25.
38. Gupta K.K., Bharne S.S., Rathinasamy K., Naik N.R., Panda D. Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS J 2006, 273:5320-5332.
39. Limtrakul P., Chearwae W., Shukla S., Phisalphong C., Ambudkar S.V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 2007, 296:85-95.
40. Chearwae W., Wu C.P., Chu H.Y., Lee T.R., Ambudkar S.V., Limtrakul P. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol 2006, 57:376-388.
41. Tang X., Bi H., Feng J., Cao J. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacologica Sinica 2005, 26:1009-1016.
42. Ganta S., Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resisrance in tumor cells. Mol Pharmaceutics 2009, 6:928-939.
43. Harbottle A., Daly A.K., Atherton K., Campbell F.C. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 2001, 92:777-783.